Nippon Kayaku announces marketing approval of infliximab biosimilar in Japan

July 7, 2014 2:55 PM

Nippon Kayaku Co., Ltd. last week announced that Nippon Kayaku has obtained the marketing approval of infliximab biosimilar for i.v. infusion 100mg NK which was developed jointly with Celltrion, Inc. and Celltrion Healthcare Co., Ltd.

This is the first monoclonal antibody biosimilar approval in Japan.

Infliximab biosimilar for i.v. infusion 100mg NK (development code: CT-P13) is a biosimilar of the infliximab monoclonal antibody that has played an important role in treatment of rheumatoid arthritis, inflammatory bowel disease and other autoimmune diseases, and has already been marketed in 25 countries including South Korea and Europe. Nippon Kayaku began development of this biosimilar in November 2010 following the conclusion of a cooperation agreement with the Celltrion Group.

Infliximab biosimilar for i.v. infusion 100mg NK is the second biosimilar for Nippon Kayaku following filgrastim biosimilar inj, which was marketed last year. In the field of autoimmune diseases, since 2001 Nippon Kayaku has marketed Saligren® Cap. 30mg, a drug for treatment of dry-mouth symptoms among patients suffering from Sjögren’s syndrome. With the marketing of infliximab biosimilar for i.v. infusion 100mg NK, the company expects to make an even greater contribution to patients with rheumatoid arthritis and inflammatory bowel disease, their families and medical professionals.


Source: Nippon Kayaku press release

1 Comment


    Dear sir,kindly mention the price of the i.v. infusion 100mg NK TNF Inhibitor for 100 mg bottle and dosage per kg ,WHERE IT AVAILABLE IN INDIA?

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!